Diagnostica Stago Inc, Product Pipeline Analysis 2019 Update: Venoms, Activators, Purified Proteins, Coagulation Factors, Inhibitors, Chromogenic Substrates, Lupus Inhibitors & Heparin Anti-Xa Assays - ResearchAndMarkets.com

The "Diagnostica Stago Inc - Product Pipeline Analysis, 2019 Update" company profile has been added to ResearchAndMarkets.com's offering.

Summary

Diagnostica Stago Inc (Stago), a subsidiary of Diagnostica Stago SAS, is a medical device company that develops and distributes in-vitro diagnostic products. It develops coagulation automation systems. It provides products such as hemostasis analyzers, viscosity based detection systems, reagents and research products. Stago's research and reagent products includes venoms, activators, purified proteins, coagulation factors, inhibitors, chromogenic substrates, lupus inhibitors, heparin anti-xa assays, coagulation inhibitors, fibrin and fibrinogen degradation products, among others. The company offers various customer services such as proficiency testing, field technical support, education and customer training. It also offers hemostasis proficiency testing program and peer group program. The company operates in the US and Canada. Stago is headquartered in Parsippany, New Jersey, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

• The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
• The report analyzes all pipeline products in development for the company Diagnostica Stago Inc
• The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
• The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
• The report provides detailed description of products in development, technical specification and functions
• The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

• Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
• Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
• To formulate effective Research & Development strategies
• Develop market-entry and market expansion strategies
• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
• Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Key Topics Covered:

• Diagnostica Stago Inc Company Overview
• Diagnostica Stago Inc Company Snapshot
• Diagnostica Stago Inc Pipeline Products and Ongoing Clinical Trials Overview
• Diagnostica Stago Inc - Pipeline Analysis Overview
• Diagnostica Stago Inc - Key Facts
• Diagnostica Stago Inc - Major Products and Services
• Diagnostica Stago Inc Pipeline Products by Development Stage
• Calibrated Automated Thrombogram - Thrombin Assay
• STA Compact Max - Apixaban Calibrators And Controls
• STA Compact Max - Dabigatran Calibrator And Control
• STA Compact Max - Edoxaban Calibrator And Control
• STA Compact Max - NeoPTimal ISI
• STA Compact Max - Ristocetin Cofactor Assay
• STA Compact Max - Rivaroxaban Calibrators And Controls For Anti-Xa
• STA-R Evolution Expert - Automated Ecarin Chromogenic Assay
• STA-R Evolution Expert - Rivaroxaban and Apixaban Calibrators And Controls For Anti-Xa
• STA-R Evolution Plus - Automated Ecarin Chromogenic Assay
• STA-R Evolution Plus - Rivaroxaban and Apixaban Calibrators And Controls For Anti-Xa
• STA-R Max - Apixaban Calibrators And Controls
• STA-R Max - Dabigatran Calibrator And Control
• STA-R Max - Edoxaban Calibrator And Control
• STA-R Max - NeoPTimal ISI
• STA-R Max - Ristocetin Cofactor Assay
• STA-R Max - Ristocetin Cofactor Assay Product Overview
• STA-R Max - Rivaroxaban Calibrators And Controls For Anti-Xa
• STA-R Max - Rivaroxaban Calibrators And Controls For Anti-Xa Product Overview
• Diagnostica Stago Inc - Key Competitors
• Diagnostica Stago Inc - Key Employees
• Diagnostica Stago Inc - Locations And Subsidiaries
• Head Office
• Other Locations & Subsidiaries
• Recent Developments
• Diagnostica Stago Inc, Recent Developments
• Sep 16, 2014: Stago's D-Dimer test, 1st assay to meet the new CLSI H59-A standards for exclusion of PE
• Aug 18, 2009: Diagnostica Stago Opens New Training Center
• May 04, 2009: Instrumentation Laboratory Wins Patent Infringement And Unfair Competition Trial Against Diagnostica Stago Relating To Reagents For Hemostasis Diagnostics
• Appendix
• Methodology
• About the Author
• Contact Us
• Disclaimer

Companies Mentioned

• Helena Laboratories Corp
• BioMed Diagnostics Inc
• Alfa Wassermann Diagnostic Technologies, LLC

For more information about this company profile visit https://www.researchandmarkets.com/r/4aefd6

View source version on businesswire.com: https://www.businesswire.com/news/home/20200120005290/en/